3,5-Dinitrocatechol
Based on 1 Customer Validation
3,5-Dinitrocatechol (OR-486) is an orally active, blood-brain barrier-permeable selective catechol-O-methyltransferase (COMT) inhibitor. 3,5-Dinitrocatechol can be used in research related to Parkinson's disease, pheochromocytoma and adult cataract.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.72%
- CAS. Nr.: 7659-29-2
- Formel: C6H4N2O6
- Molecular Weight:200.11
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-10038
A 922500 -
HY-17406
Tolcapone -
HY-100959R
3,5-Dinitrocatechol (Standard) -
HY-W020050
Cystamine dihydrochloride -
HY-13009
PF-04620110 -
HY-W018864
Tris(dibenzylideneacetonyl)bis-palladium -
HY-50876
Daporinad -
HY-A0098
Tunicamycin -
HY-14280
Entacapone -
HY-15879
LB42708 -
HY-10502
Tipifarnib -
HY-15136
Lonafarnib
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | EC50 |
22 μM
Compound: 3,5-Dinitrocatechol
|
Agonist activity at GPR35 in human HT-29 cells assessed as induction of whole cell dynamic mass redistribution after 50 mins by resonant waveguide grating biosensor analysis
Agonist activity at GPR35 in human HT-29 cells assessed as induction of whole cell dynamic mass redistribution after 50 mins by resonant waveguide grating biosensor analysis
|
10.1039/C2MD20210G |
| U2OS | EC50 |
123 μM
Compound: 3,5-Dinitrocatechol
|
Agonist activity at GPR35 in human U2OS cells assessed as induction of beta-arrestin translocation after 5 hrs by beta-lactamase reporter gene assay
Agonist activity at GPR35 in human U2OS cells assessed as induction of beta-arrestin translocation after 5 hrs by beta-lactamase reporter gene assay
|
10.1039/C2MD20210G |
In Vitro
3,5-Dinitrocatechol (OR-486) inhibits catechol-O-methyltransferase (COMT) in HUVEC, attenuating the nitric oxide-preserving and cyclic GMP-elevating effects of (-)-Epicatechin (HY-N0001) in Angiotensin II (Angiotensin II human) (HY-13948)-stimulated cells[4].
3,5-Dinitrocatechol (OR-486) (0.005-50 μM) potently and selectively inhibits rat brain soluble COMT activity with an IC50 of 12 nM, while showing weak inhibition of tyrosine hydroxylase and no inhibition of other tested catecholamine-metabolizing enzymes at concentrations up to 50 μM[1].
3,5-Dinitrocatechol (20 min preincubation, 15 min substrate incubation) is more potent against rat brain membrane-bound MB-COMT (IC50 = 3 nM) than against rat brain soluble S-COMT (IC50 = 28 nM) when assayed with a fixed total protein concentration of 2 mg/mL[5].
3,5-Dinitrocatechol (20 min preincubation, 5 min substrate incubation) is more potent against rat liver membrane-bound MB-COMT (IC50 = 11 nM) than against rat liver soluble S-COMT (IC50 = 356 nM) when assayed with a fixed total protein concentration of 2 mg/mL[5].
3,5-Dinitrocatechol (20 min preincubation, 5 min substrate incubation) shows similar potency against rat liver membrane-bound MB-COMT (IC50 = 3 nM) and rat liver soluble S-COMT (IC50 = 6 nM) when assayed with a fixed enzyme concentration of 15 nM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
3,5-Dinitrocatechol (0.3-30 mg/kg; p.o.; single dose) is an orally active, long-lasting inhibitor of peripheral COMT in rats, with an ID50 of 0.20 mg/kg for duodenal COMT, 0.26 mg/kg for RBC COMT, and 2.6 mg/kg for liver COMT 1 h post-dose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 190-230 g)[1]
-
Dosage:0.20 mg/kg (duodenal COMT ID50); 0.26 mg/kg (RBC COMT ID50); 2.6 mg/kg (liver COMT ID50); >30 mg/kg (striatal COMT ID50); 3 mg/kg (activity inhibition)
-
Administration:p.o.; single dose
-
Result:Inhibited duodenal COMT activity by 65% at 12 h post-administration, with full recovery by 24 h.
Markedly inhibited RBC and liver COMT activities for 8 h post-administration.
Inhibited striatal COMT activity by 30% 15 min post-administration, decreasing to ~15% inhibition that persisted for 5 h.
Achieved an ID50 of 0.20 mg/kg for duodenal COMT inhibition 1 h post-administration.
Achieved an ID50 of 0.26 mg/kg for RBC COMT inhibition 1 h post-administration.
Achieved an ID50 of 2.6 mg/kg for liver COMT inhibition 1 h post-administration.
Had a striatal COMT ID50 greater than 30 mg/kg 1 h post-administration.
-
Animal Model:Wistar rats (male, 190-230 g, pretreated with Carbidopa to inhibit aromatic L-amino acid decarboxylase)[1]
-
Dosage:0.3 mg/kg (ED50 for 3OMD reduction); 3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:p.o.; single dose; co-administered with Levodopa
-
Result:Caused a dose-dependent reduction in serum 3OMD formation.
Caused a dose-dependent increase in serum Levodopa concentrations, with Levodopa levels remaining elevated longer than with Levodopa-Carbidopa alone.
Achieved an ED50 of 0.3 mg/kg for reduction in serum 3OMD formation.
Chemical Information
-
CAS. Nr. 7659-29-2
-
Appearance Solid
-
Molecular Weight 200.11
-
Formel C6H4N2O6
-
Color Light yellow to yellow
-
SMILES
OC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O
-
Synonyms
OR-486; 3,5-Dinitropyrocatechol
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (499.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (5.00 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (292 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Nissinen E, et al. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. European journal of pharmacology. 1988 Aug 24;153(2-3):263-9. [Content Brief]
[2]. Yamaki F, et al. Effects of Catecholamine Metabolites on Beta-Adrenoceptor-Mediated Relaxation of Smooth Muscle: Evaluation in Mouse and Guinea-Pig Trachea and Rat Aorta. Biological & pharmaceutical bulletin. 2020;43(3):493-502. [Content Brief]
[5]. Vieira-Coelho MA, et al. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain research. 1999 Mar 06;821(1):69-78. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.9973 mL | 24.9863 mL | 49.9725 mL | 124.9313 mL |
| DMSO | 10 mM | 0.4997 mL | 2.4986 mL | 4.9973 mL | 12.4931 mL |
| 15 mM | 0.3332 mL | 1.6658 mL | 3.3315 mL | 8.3288 mL | |
| 20 mM | 0.2499 mL | 1.2493 mL | 2.4986 mL | 6.2466 mL | |
| 25 mM | 0.1999 mL | 0.9995 mL | 1.9989 mL | 4.9973 mL | |
| 30 mM | 0.1666 mL | 0.8329 mL | 1.6658 mL | 4.1644 mL | |
| 40 mM | 0.1249 mL | 0.6247 mL | 1.2493 mL | 3.1233 mL | |
| 50 mM | 0.0999 mL | 0.4997 mL | 0.9995 mL | 2.4986 mL | |
| 60 mM | 0.0833 mL | 0.4164 mL | 0.8329 mL | 2.0822 mL | |
| 80 mM | 0.0625 mL | 0.3123 mL | 0.6247 mL | 1.5616 mL | |
| 100 mM | 0.0500 mL | 0.2499 mL | 0.4997 mL | 1.2493 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
3,5-Dinitrocatechol Related Classifications
HY-100959 Related Classifications
Powered by Bioz